---
input_text: 'Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized
  controlled trials. OBJECTIVE: The efficacy of cannabidiol (CBD) with and without
  concomitant clobazam (CLB) was evaluated in stratified analyses of four large randomized
  controlled trials, two in Lennox-Gastaut syndrome, and two in Dravet syndrome. METHODS:
  Each trial of CBD (Epidiolex  in the US; Epidyolex  in the EU; 10 and 20 mg/kg/day)
  was evaluated by CLB use. The treatment ratio was analyzed using negative binomial
  regression for changes in seizure frequency and logistic regression for the 50%
  responder rate, where the principle analysis combined both indications and CBD doses
  in a stratified meta-analysis. Pharmacokinetic data were examined for an exposure/response
  relationship based on CLB presence/absence. Safety data were analyzed using descriptive
  statistics. RESULTS: The meta-analysis favored CBD vs. placebo regardless of CLB
  use. The treatment ratio (95% CI) of CBD over placebo for the average reduction
  in seizure frequency was 0.59 (0.52, 0.68; P < .0001) with CLB and 0.85 (0.73, 0.98;
  P = .0226) without CLB, and the 50% responder rate odds ratio (95% CI) was 2.51
  (1.69, 3.71; P < .0001) with CLB and 2.40 (1.38, 4.16; P = .0020) without CLB. Adverse
  events (AEs) related to somnolence, rash, pneumonia, or aggression were more common
  in patients with concomitant CLB. There was a significant exposure/response relationship
  for CBD and its active metabolite. CONCLUSIONS: These results indicate CBD is efficacious
  with and without CLB, but do not exclude the possibility of a synergistic effect
  associated with the combination of agents. The safety and tolerability profile of
  CBD without CLB show a lower rate of certain AEs than with CLB.'
raw_completion_output: |-
  primary_disease: Lennox-Gastaut syndrome; Dravet syndrome
  medical_actions: Administration of cannabidiol (CBD); Administration of clobazam (CLB); Meta-analysis of randomized controlled trials; Negative binomial regression analysis; Logistic regression analysis; Examination of pharmacokinetic data; Descriptive statistics analysis for safety data
  symptoms: Seizure frequency; Somnolence; Rash; Pneumonia; Aggression
  chemicals: Cannabidiol (CBD); Clobazam (CLB)
  action_annotation_relationships: Administration of cannabidiol (CBD) TREATS Seizure frequency IN Lennox-Gastaut syndrome; Administration of cannabidiol (CBD) TREATS Seizure frequency IN Dravet syndrome; Administration of cannabidiol (CBD) with clobazam (CLB) TREATS Seizure frequency IN Lennox-Gastaut syndrome; Administration of cannabidiol (CBD) with clobazam (CLB) TREATS Seizure frequency IN Dravet syndrome; Administration of cannabidiol (CBD) PREVENTS Somnolence IN Lennox-Gastaut syndrome; Administration of cannabidiol (CBD) PREVENTS Rash IN Dravet syndrome; Administration of cannabidiol (CBD) PREVENTS Pneumonia IN Lennox-Gastaut syndrome; Administration of cannabidiol (CBD) PREVENTS Aggression IN Dravet syndrome
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Administration of cannabidiol (CBD) PREVENTS Aggression IN Dravet syndrome

  ===

extracted_object:
  primary_disease: Lennox-Gastaut syndrome; Dravet syndrome
  medical_actions:
    - Administration of cannabidiol (CBD)
    - Administration of clobazam (CLB)
    - Meta-analysis of randomized controlled trials
    - Negative binomial regression analysis
    - Logistic regression analysis
    - Examination of pharmacokinetic data
    - Descriptive statistics analysis for safety data
  symptoms:
    - Seizure frequency
    - HP:0002329
    - HP:0000988
    - HP:0002090
    - HP:0000718
  chemicals:
    - CHEBI:69478
    - CHEBI:31413
  action_annotation_relationships:
    - subject: Administration of cannabidiol (CBD)
      predicate: TREATS
      object: Seizure frequency
      qualifier: MONDO:0016532
      subject_extension: CHEBI:69478
    - subject: Administration of cannabidiol
      predicate: TREATS
      object: Seizure frequency
      qualifier: MONDO:0100135
      subject_extension: CHEBI:69478
    - subject: Administration
      predicate: TREATS
      object: Seizure frequency
      qualifier: MONDO:0016532
      subject_extension: cannabidiol (CBD) with clobazam (CLB)
    - subject: Administration
      predicate: TREATS
      object: Seizure frequency
      qualifier: MONDO:0100135
      subject_extension: cannabidiol (CBD) with clobazam (CLB)
    - subject: Administration of cannabidiol
      predicate: PREVENTS
      object: HP:0002329
      qualifier: MONDO:0016532
      subject_extension: CHEBI:69478
    - subject: Administration of cannabidiol
      predicate: PREVENTS
      object: HP:0000988
      qualifier: MONDO:0100135
      subject_extension: CHEBI:69478
    - subject: Administration of cannabidiol
      predicate: PREVENTS
      object: HP:0002090
      qualifier: MONDO:0016532
      subject_extension: CHEBI:69478
    - subject: Administration of cannabidiol (CBD)
      predicate: PREVENTS
      object: HP:0000718
      qualifier: MONDO:0100135
      subject_extension: CHEBI:69478
named_entities:
  - id: MONDO:0100135
    label: Dravet syndrome
  - id: MAXO:0001187
    label: hysteroscopy
  - id: CHEBI:44915
    label: propofol
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:9130
    label: sevoflurane
  - id: HP:0001250
    label: seizures
  - id: CHEBI:6443
    label: Mirena
  - id: MONDO:0002602
    label: Central nervous system diseases
  - id: HP:0002011
    label: central nervous system diseases
  - id: MONDO:0005027
    label: Epilepsy
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0000988
    label: Rash
  - id: CHEBI:228488
    label: Stiripentol
  - id: CHEBI:60654
    label: Valproate
  - id: CHEBI:69478
    label: Cannabidiol
  - id: CHEBI:80634
    label: 2-propyl-4-pentenoic acid (4-ene-VPA)
  - id: HP:0002373
    label: Febrile seizures
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:31413
    label: clobazam (CLB)
  - id: HP:0010819
    label: drop seizures
  - id: HP:0002329
    label: somnolence
  - id: HP:0004396
    label: decreased appetite
  - id: CHEBI:9925
    label: sodium valproate
  - id: MONDO:0016532
    label: Lennox-Gastaut syndrome
  - id: HP:0000729
    label: Autistic behaviors
  - id: HP:0033258
    label: Sudden unexpected death in epilepsy
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0002125
    label: Status epilepticus
  - id: HP:0032656
    label: Febrile status epilepticus
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0002069
    label: Generalized tonic-clonic seizure
  - id: CHEBI:3359
    label: CBDA
  - id: CHEBI:167557
    label: CBCA
  - id: CHEBI:66964
    label: Delta9-tetrahydrocannabinol (THC)
  - id: CHEBI:39867
    label: Valproic acid
  - id: CHEBI:5000
    label: Fenfluramine
  - id: HP:0033349
    label: recurrent seizures
  - id: MAXO:0000058
    label: Drug treatment
  - id: HP:0020219
    label: motor seizures
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: MAXO:0001593
    label: ASO therapy
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001945
    label: Pyrexia
  - id: HP:0001654
    label: valvular heart disease
  - id: HP:0002092
    label: pulmonary arterial hypertension
  - id: HP:0002133
    label: Status epilepticus
  - id: CHEBI:17115
    label: vaccine(s)
  - id: MONDO:0100062
    label: Developmental and/or epileptic encephalopathies (DEE)
  - id: HP:0001260
    label: dysarthria
  - id: HP:0001254
    label: lethargy
  - id: HP:0002315
    label: headache
  - id: CHEBI:233158
    label: soticlestat
  - id: CHEBI:34310
    label: 24S-hydroxycholesterol (24HC)
  - id: CHEBI:9586
    label: Tiagabine
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0000708
    label: behavioral problems
  - id: CHEBI:16113
    label: Cholesterol
  - id: MAXO:0001394
    label: Oral administration
  - id: CHEBI:173124
    label: 2-linoleoyl glycerol (2-LG)
  - id: CHEBI:52392
    label: 2-AG
  - id: CHEBI:2700
    label: anandamide
  - id: CHEBI:52640
    label: N-acylethanolamines
  - id: CHEBI:35623
    label: Anticonvulsants
  - id: MAXO:0000942
    label: Vagus nerve stimulation (VNS)
  - id: HP:0002360
    label: Sleep disturbance
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:42638
    label: fenfluramine (FFA)
  - id: HP:0032794
    label: Myoclonic seizures
  - id: CHEBI:190616
    label: N-desmethylclobazam
  - id: MONDO:0013801
    label: SCN8A encephalopathy
  - id: HP:0001263
    label: Developmental delay
  - id: HP:0100543
    label: Cognitive impairment
  - id: CHEBI:35493
    label: antipyretics
  - id: MAXO:0000932
    label: Electroencephalography (EEG)
  - id: HP:0002353
    label: EEG abnormalities
  - id: CHEBI:73601
    label: <Ketogenic diet (KD)>
  - id: CHEBI:49575
    label: diazepam
  - id: CHEBI:6931
    label: midazolam
  - id: CHEBI:3756
    label: clonazepam
  - id: CHEBI:22720
    label: Benzodiazepines
  - id: MONDO:0010083
    label: Succinic semialdehyde dehydrogenase deficiency
  - id: HP:0000739
    label: Anxiety
  - id: CHEBI:10127
    label: Zonisamide
  - id: CHEBI:87016
    label: Eslicarbazepine acetate
  - id: CHEBI:135939
    label: Lacosamide
  - id: MONDO:0700092
    label: Neurodevelopmental disorders (NDDs)
  - id: CHEBI:63631
    label: Topiramate
  - id: CHEBI:15858
    label: Bromides
  - id: MAXO:0000127
    label: Genetic testing
  - id: MONDO:0008297
    label: Vaccine proximate seizures (VPS)
  - id: MAXO:0000943
    label: deep brain stimulation (DBS)
  - id: MAXO:0000940
    label: responsive neurostimulation (RNS)
  - id: MONDO:0005071
    label: Neurological disorders
  - id: CHEBI:133053
    label: 7-OH-CBD
  - id: MONDO:0002049
    label: Thrombocytopenia
  - id: HP:0001873
    label: thrombocytopenia
  - id: CHEBI:8107
    label: Phenytoin
  - id: HP:0012758
    label: Neurodevelopmental delays
  - id: HP:0011951
    label: Aspiration pneumonia
  - id: CHEBI:71013
    label: Perampanel
  - id: CHEBI:63004
    label: Sodium bromide
  - id: HP:0002090
    label: Pneumonia
  - id: HP:0000718
    label: Aggression
